AdvaMed on competitive bidding
This article was originally published in The Gray Sheet
In Oct. 6 1comments, AdvaMed reiterates durable medical equipment suppliers' concerns about beneficiary access to quality products, initially raised at CMS' Sept. 27-28 Program Advisory & Oversight Committee meeting on the impending DME competitive bidding program (2"The Gray Sheet" Oct. 3, 2005, p. 15). AdvaMed also asks CMS to consider the role of small pharmacies as product suppliers, and to look at how small manufacturers that directly supply single products might be included in the program. The trade group will submit comments on the proposed quality standards discussed at the meeting as well (3"The Gray Sheet" Oct. 3, 2005, p. 16)...
You may also be interested in...
CMS draft quality standards for DMEPOS suppliers may be too prescriptive and could exclude small suppliers from participating in competitive bidding, Program Advisory & Oversight Committee members suggested Sept. 26
Supplier and manufacturer stakeholders are urging CMS to exclude blood glucose testing products from the impending DMEPOS competitive bidding program
US FDA considering approach that is similar to, but more stringent than, influenza strain changes, CBER Director Marks says. But how to know what variants need a limited study and which one need a big one will be an ongoing challenge, NIH's Graham notes. As FDA and sponsors gain more experience with tweaking the vaccines to account for new coronavirus variants and strains, the process may be expedited further.